Eloxx Pharmaceuticals, Inc. (ELOX)
15.00
+0.81
(+5.71%)
USD |
OTCM |
Sep 04, 16:00
14.70
-0.30
(-2.00%)
After-Hours: 20:00
Eloxx Pharmaceuticals Research and Development Expense (Quarterly) : 2.84M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.84M |
| March 31, 2026 | 1.659M |
| June 30, 2025 | 0.898M |
| September 30, 2023 | 1.25M |
| June 30, 2023 | 2.338M |
| March 31, 2023 | 3.488M |
| December 31, 2022 | 3.297M |
| September 30, 2022 | 4.88M |
| June 30, 2022 | 7.651M |
| March 31, 2022 | 7.899M |
| December 31, 2021 | 7.912M |
| September 30, 2021 | 5.21M |
| June 30, 2021 | 5.704M |
| March 31, 2021 | 4.073M |
| December 31, 2020 | 2.64M |
| September 30, 2020 | 3.231M |
| June 30, 2020 | 3.528M |
| March 31, 2020 | 4.549M |
| December 31, 2019 | 5.682M |
| September 30, 2019 | 6.801M |
| June 30, 2019 | 7.34M |
| March 31, 2019 | 6.019M |
| December 31, 2018 | 6.53M |
| September 30, 2018 | 5.415M |
| June 30, 2018 | 4.15M |
| Date | Value |
|---|---|
| March 31, 2018 | 4.013M |
| June 30, 2017 | 0.1101M |
| March 31, 2017 | 0.1173M |
| December 31, 2016 | 0.1934M |
| September 30, 2016 | 0.2686M |
| June 30, 2016 | 0.3981M |
| March 31, 2016 | 0.5574M |
| December 31, 2015 | 0.5645M |
| September 30, 2015 | 0.5695M |
| June 30, 2015 | 0.8411M |
| March 31, 2015 | 0.2353M |
| December 31, 2014 | 1.334M |
| September 30, 2014 | 2.120M |
| June 30, 2014 | 1.089M |
| March 31, 2014 | 0.8752M |
| December 31, 2013 | 0.6471M |
| September 30, 2013 | 0.7271M |
| June 30, 2013 | 0.4449M |
| March 31, 2013 | 0.4928M |
| December 31, 2012 | 0.5911M |
| September 30, 2012 | 0.5134M |
| June 30, 2012 | 0.6398M |
| March 31, 2012 | 0.5408M |
| December 31, 2011 | 0.7515M |
| September 30, 2011 | 0.6342M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Filana Therapeutics, Inc. | 3.303M |
| CorMedix, Inc. | 6.684M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 0.0041M |
| BioStem Technologies, Inc. | 0.7336M |